A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults
Allergy · 2026
DOI: 10.1111/all.70265 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2026. Verfasst von Marek Jutel und 5 weiteren Autor:innen. Beteiligte Einrichtung: All-MED Medical Research Institute, Wrocław, Poland. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Betula, Pollen, Allergens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Allergopharma GmbH & Co. KG, Reinbek, Germany.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Allergen immunotherapy is the only disease‐modifying treatment for IgE‐mediated diseases for patients 5 years and over. The question is often asked why children receive the same doses as adults. There is not a single dose‐finding study including children and/or adolescents. Moreover, randomized controlled trials that include all age groups but report effects separately are rare.
Method
This randomized trial investigated the safety and tolerability of an accelerated dose escalation schedule (One‐Strength group) compared to the standard regimen (Standard group) when using a birch pollen SCIT allergoid in patients aged 5–65 years.
Results
Overall, 201 patients were randomized to the two regimens: 87 adults, 52 adolescents, 62 children. Three hundred eighty‐two treatment‐related adverse drug reactions (ADRs) occurred in 81 patients (40.5%). A higher proportion of patients in the One‐Strength group (48.5%) experienced at least one ADR compared to those in the Standard group (32.0%). The majority of ADRs were local (93.3%), and the majority were of mild intensity (95.8%). 3 patients in the One‐Strength and 1 patient in the Standard group developed a total of 9 systemic ADRs, which all were classified as WAO grade 1 or 2 and most of mild intensity. No event of WAO grade 3 or higher was reported. No serious ADR occurred. Overall, tolerability was assessed as “very good” or “good” by more than 96% of investigators and patients. Safety and tolerability were comparable in the three age groups.
Conclusion
Birch pollen SCIT was safe and well‐tolerated when administered using a One‐Strength dose‐escalation regimen in patients aged 5–65 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- All-MED Medical Research Institute, Wrocław, Poland.
- Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland.
- Center for Rhinology and Allergology, Wiesbaden, Germany.
- Pediatric and Adolescent Medicine, University Hospital Augsburg, Augsburg, Germany.
- Allergopharma GmbH & Co. KG, Reinbek, Germany.
- Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
ORCID-Profile: Marek Jutel, Ludger Klimek, Michael Gerstlauer, Christian Vogelberg
Förderung
- Allergopharma GmbH & Co. KG, Reinbek, Germany
Zitieren
APA
Jutel, M., Klimek, L., Gerstlauer, M., Troyke, D., Duwensee, K., & Vogelberg, C. (2026). A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults. Allergy. https://doi.org/10.1111/all.70265
Vancouver
Jutel M, Klimek L, Gerstlauer M, Troyke D, Duwensee K, Vogelberg C. A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults. Allergy. 2026. doi:10.1111/all.70265
BibTeX
@article{Jutel2026,
author = {Jutel, Marek and Klimek, Ludger and Gerstlauer, Michael and Troyke, Dana and Duwensee, Kristina and Vogelberg, Christian},
title = {A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70265}
}
EUVIMED